Molecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and Prevention
Open accessThe DOI matches its Crossref record; 133 of the 140 references it cites were found in a registry or an index.
Abstract
Research conducted during the past 30 years has increased our understanding of the mechanisms involved in colorectal cancer initiation and development. The findings have demonstrated the existence of at least three pathways: chromosomal instability, microsatellite instability and CpG island methylator phenotype. Importantly, new studies have shown that inflammation and microRNAs contribute to colorectal carcinogenesis. Recent data have demonstrated that several genetic and epigenetic changes are important in determining patient prognosis and survival. Furthermore, some of these mechanisms are related to patients’ response to drugs, such as aspirin, which could be used for both chemoprevention and treatment in specific settings. Thus, in the near future, we could be able to predict disease behavior based on molecular markers found on tumors, and direct the best treatment options for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, if cells opt for senescence, they cannot return to the cell cycle [42].”
From Synergistic Potential of Argentatins A and B to Improve 5‐Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models (2024) · cites this paper as [42]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Cancer cells that enter G0 can become quiescent or senescent. If cells choose quiescence, they can become more resistant to chemotherapy, which typically targets cells that are actively dividing. Furthermore, if they choose a dormant state, this can lead to recurrence after a period of remission.”
From Synergistic Potential of Argentatins A and B to Improve 5‐Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models (2024) · cites this paper as [42]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · cited 1×
“They follow the multiple stages pattern theorized by Fearon and Vogelstein [7].”
BackgroundWAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC
Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., & Kinzler, K. W. (1997) · Science · doi:10.1126/science.275.5307.1787 · Cited by 3,942
The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer
Fishel, R., Lescoe, M. K., Rao, M. R. S., Copeland, N. G., Jenkins, N. A., Garber, J., Kane, M., & Kolodner, R. (1993) · Cell · doi:10.1016/0092-8674(93)90546-3 · Cited by 2,873 · cited 1×
“Defective hMSH2 is associated with a 40%–60% increased risk of developing endometrial cancer, while defective hMLH1 with a 50%–80% increased risk of developing CRC [65,66].”
BackgroundTerzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974 · cited 4×
“IL-6 is a cytokine involved in the regulation of the acute phase of inflammation and, in its own transduction pathway, stimulates the transcription of STAT3 [119].”
BackgroundInfluentialRAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902 · cited 1×
“More than 90% of mutations in the K-ras gene happen at codon 12 and at codon 13 [29].”
BackgroundIncidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahuja, N., Issa, J.-P. J., Markowitz, S., Willson, J. K. V., Hamilton, S. R., Kinzler, K. W., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6870 · Cited by 1,887 · cited 1×
“promoter [71–74].”
Reduced accumulation of specific microRNAs in colorectal neoplasia.
Michael, M., Connor, S. M. O., Pellekaan, N. V. H., Young, G. P., & James, R. J. (2003) · PubMed · Cited by 1,775
The impact of retrotransposons on human genome evolution
Cordaux, R., & Batzer, M. A. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2640 · Cited by 1,703 · cited 1×
“L1 elements represent approximately 17% of the human genome [49].”
Backgroundvan Es, J. H., van Gijn, M. E., Riccio, O., van den Born, M., Vooijs, M., Begthel, H., Cozijnsen, M., Robine, S., Winton, D. J., Radtke, F., et al. (2005) · Nature · doi:10.1038/nature03659 · Cited by 1,543
Kane, M., Loda, M. F., Gaida, G. M., Lipman, J., Mishra, R., Goldman, H., Jessup, J. M., & Kolodner, R. D. (1997) · PubMed · Cited by 1,476
Rothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351 · cited 2×
“Physical activity [4], long-term therapy with low-dose aspirin [5], and the Mediterranean diet [6] have proved to have possible preventive effects.”
BackgroundRampino, N., Yamamoto, H., Ionov, Y., Li, Y., Sawai, H., Reed, J. C., & Perucho, M. (1997) · Science · doi:10.1126/science.275.5302.967 · Cited by 1,326 · cited 1×
“Homozygous frameshift mutations of BAX occur in 50% of CRCs cases and promote the cell’s escape from intrinsic apoptosis mechanisms [82,83].”
BackgroundBaker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., & Vogelstein, B. (1990) · PubMed · Cited by 1,260
Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentinc, M., Draetta, G. F., Jessup, J. M., & Pagano, M. (1997) · Nature Medicine · doi:10.1038/nm0297-231 · Cited by 1,031 · cited 1×
“P27 is involved in the control of the progression into S phase of the cell cycle and its degradation is associated with CRC progression [40].”
BackgroundMutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Sparks, A. B., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · PubMed · Cited by 1,008
Analysis of mismatch repair genes in hereditary non–polyposis colorectal cancer patients
Liu, B., Parsons, R., Papadopoulos, N., Nicolaides, N. C., Lynch, H. T., Watson, P., Jass, J. R., Dunlop, M., Wyllie, A., Peltomäki, P., et al. (1996) · Nature Medicine · doi:10.1038/nm0296-169 · Cited by 945 · cited 1×
“Furthermore mutations in hMSH6 are associated with 11%–19% increased risk of developing gastric cancer [67] while mutations in hPMS2 with a 9%–12% increased risk of develop ovarian cancer [68].”
BackgroundBandrés, E., Cubedo, E., Agirre, X., Malumbres, R., Zárate, R., Ramírez, N., Abajo, A., Navarro, A., Moreno, I., Monzó, M., et al. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-29 · Cited by 884
Alao, J. P. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-24 · Cited by 871 · cited 1×
“[26] Excessive CCND1 activation by APC mutation contributes to the development of colonic neoplasia by allowing the cell to escape apoptosis.”
BackgroundMultiple Colorectal Adenomas, Classic Adenomatous Polyposis, and Germ-Line Mutations in MYH
Sieber, O. M., Lipton, L., Crabtree, M., Heinimann, K., Fidalgo, P., Phillips, R. K. S., Bisgaard, M.-L., Orntoft, T. F., Aaltonen, L. A., Hodgson, S. V., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025283 · Cited by 862 · cited 1×
“Phenotypically AFAP and MAP are very similar [15].”
BackgroundCarmon, K. S., Gong, X., Lin, Q., Thomas, A., & Liu, Q. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106083108 · Cited by 855 · cited 1×
“The authors found that the increased Wnt/β-Catenin activity is obtained through enhanced WNT co-receptor LRP6 phosphorylation [25].”
BackgroundEppert, K., Scherer, S. W., Ozcelik, H., Pirone, R., Hoodless, P., Kim, H., Tsui, L.-C., Bapat, B., Gallinger, S., Andrulis, I. L., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)80128-2 · Cited by 845 · cited 1×
“function of Smad2 contributes, independently of Smad4, to deactivated TGF-β signaling [80].”
BackgroundAspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Liao, X., Lochhead, P., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., Imamura, Y., Qian, Z. R., Baba, Y., Shima, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207756 · Cited by 843 · cited 2×
“PI3KCA mutations Increased survival among chronic aspirin users [48] Line-1 Hypomethylation Young age of onset and increased cancer and overall mortality [50,51] HIF1 High colorectal cancer-specific mortality [55] Cathepsin B expression High colorectal cancer and overall mortality [57] MSI Better prognosis and surviva…”
BackgroundOgino, S., Nosho, K., Kirkner, G. J., Kawasaki, T., Meyerhardt, J. A., Loda, M., Giovannucci, E. L., & Fuchs, C. S. (2009) · Gut · doi:10.1136/gut.2008.155473 · Cited by 777 · cited 3×
“is associated with increased cell growth, progression of carcinogenesis, and high colon cancer specific mortality [99].”
BackgroundCummins, J. M., He, Y., Leary, R. J., Pagliarini, R., Diaz, L. A., Sjoblom, T., Barad, O., Bentwich, Z., Szafranska, A. E., Labourier, E., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511155103 · Cited by 744 · cited 1×
“expression is reduced in precancerous adenomatous polyps, as compared to normal tissue; thus, researchers suggest these miRNAs play a key role in the early development of the tumors [113–115].”
BackgroundBRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum
Kambara, T., Simms, L. A., Whitehall, V. L. J., Spring, K. J., Wynter, C. V. A., Walsh, M. D., Barker, M. A., Arnold, S., McGivern, A., Matsubara, N., et al. (2004) · Gut · doi:10.1136/gut.2003.037671 · Cited by 722 · cited 1×
“MSI-high features; thus, researchers established that, in sporadic settings, CIMP-high microsatellite unstable CRCs derive from the serrated pathway [101].”
BackgroundCDK8 is a colorectal cancer oncogene that regulates β-catenin activity
Firestein, R., Bass, A. J., Kim, S. Y., Dunn, I. F., Silver, S. J., Guney, I., Freed, E., Ligon, A. H., Vena, N., Ogino, S., et al. (2008) · Nature · doi:10.1038/nature07179 · Cited by 672 · cited 1×
“β-Catenin [22] and Notch1, thus increasing transcription and cell differentiation [23].”
BackgroundVeigl, M. L., Kasturi, L., Olechnowicz, J., Ma, A., Lutterbaugh, J. D., Periyasamy, S., Li, G.-M., Drummond, J., Modrich, P. L., Sedwick, W. D., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8698 · Cited by 648 · cited 1×
“promoter [71–74].”
Mastermind Recruits CycC:CDK8 to Phosphorylate the Notch ICD and Coordinate Activation with Turnover
Fryer, C. J., White, J. B., & Jones, K. A. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.10.014 · Cited by 627 · cited 1×
“β-Catenin [22] and Notch1, thus increasing transcription and cell differentiation [23].”
BackgroundAaltonen, L. A., Peltomäki, P., Mecklin, J., Järvinen, H., Jass, J. R., Green, J. S., Lynch, H. T., Watson, P. A., TALLQVIST, G., & Juhola, M. (1994) · PubMed · Cited by 621
Molecular Diagnosis of Familial Adenomatous Polyposis
Powell, S. M., Petersen, G. M., Krush, A. J., Booker, S., Jen, J., Giardiello, F. M., Hamilton, S. R., Vogelstein, B., & Kinzler, K. W. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292702 · Cited by 599 · cited 6×
“A “key” initial mutation is the early mutation of the adenomatous polyposis coli (APC) tumor suppressor gene, involved in both sporadic CIN and, when germline mutated, in all Familial Adenomatous Polyposis (FAP) [12,13].”
BackgroundInfluentialSamowitz, W. S., Albertsen, H., Herrick, J., Levin, T. R., Sweeney, C., Murtaugh, M. A., Wolff, R. K., & Slattery, M. L. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.020 · Cited by 577 · cited 1×
“(CIMP) [92,93].”
Spring, K. J., Zhao, Z. Z., Karamatic, R., Walsh, M. D., Whitehall, V. L. J., Pike, T., Simms, L. A., Young, J., James, M., Montgomery, G. W., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.038 · Cited by 566 · cited 1×
“In SSA, BRAF mutations were found either in early hyperplastic polyps (the serrated precursors) or in the advanced dysplastic serrated polyps, confirming its role in neoplastic progression [100–102].”
BackgroundIntegrated genetic and epigenetic analysis identifies three different subclasses of colon cancer
Shen, L., Toyota, M., Kondo, Y., Lin, E., Zhang, L., Guo, Y., Hernandez, N. S., Chen, X., Ahmed, S., Konishi, K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704652104 · Cited by 559 · cited 1×
“(CIMP) [92,93].”
Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer)
Vasen, H. F. A., Möslein, G., Alonso, A., Bernstein, I., Bertario, L., Blanco, I., Burn, J., Capella, G., Engel, C., Frayling, I., et al. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2007.048991 · Cited by 554
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Velculescu, V. E. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1164 · Cited by 538
O'Brien, M. J., Yang, S., Mack, C., Xu, H., Huang, C. S., Mulcahy, E., Amorosino, M., & Farraye, F. A. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213313.36306.85 · Cited by 509
Souza, R. F., Appel, R., Yin, J., Wang, S., Smolinski, K. N., Abraham, J. M., Zou, T.-T., Shi, Y.-Q., Lei, J., Cottrell, J., et al. (1996) · Nature Genetics · doi:10.1038/ng1196-255 · Cited by 445 · cited 1×
“5%), Insulin Growth Factor Type 2 Receptor (IGFIIR) (22%), BLM gene (16%), PIK3CA (15%), G protein-coupled receptor of Prostaglandin-endoperoxide synthase 2 (PTGS2) (33%) and Cyclin D1 gene (28%) [86–90].”
BackgroundCorvinus, F. M., Orth, C., Moriggl, R., Tsareva, S. A., Wagner, S., Pfitzner, E. B., Baus, D., Kaufman, R., Huber, L. A., Zatloukal, K., et al. (2005) · Neoplasia · doi:10.1593/neo.04571 · Cited by 427 · cited 4×
“Interestingly, COX-2-positive tumors were found to be associated with an increased cancer-specific mortality regardless of p53 status, indicating that COX-2 could be an independent prognostic factor of colorectal cancers [42].”
BackgroundInfluentialEvidence that genetic instability occurs at an early stage of colorectal tumorigenesis.
Shih, I., Zhou, W. J., Goodman, S. N., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (2001) · PubMed · Cited by 385
Chan, G. K. T., Jablonski, S. A., Sudakin, V., Hittle, J. C., & Yen, T. J. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.5.941 · Cited by 376 · cited 1×
“By binding to Cdc20 it inhibits APC activity by stimulating a “wait anaphase” signal [18].”
BackgroundSerrated adenomatous polyposis in humans
Torlakovic, E., & Snover, D. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8608884 · Cited by 367 · cited 1×
“In SSA, BRAF mutations were found either in early hyperplastic polyps (the serrated precursors) or in the advanced dysplastic serrated polyps, confirming its role in neoplastic progression [100–102].”
BackgroundOver- and under-expressed microRNAs in human colorectal cancer
Mori (2009) · International Journal of Oncology · doi:10.3892/ijo_00000233 · Cited by 348 · cited 1×
“demonstrated an increased expression of miR-31, miR-183, miR-17-5p, miR18a, miR-20a and miR-92 in tumoral tissue as compared to normal colorectal mucosa, and saw an association between overexpression of miR-18a and a worse CRC prognosis [115].”
BackgroundAllelic Loss in Colorectal Carcinoma
Kern, S. E. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03420210047014 · Cited by 331
Cancer in inflammatory bowel disease
Xie, J., & Itzkowitz, S. H. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.378 · Cited by 328
Germ-line msh6 mutations in colorectal cancer families.
Kolodner, R. D., Tytell, J. D., Schmeits, J. L., Kane, M., Gupta, R. D., Weger, J., Wahlberg, S., Fox, E. A., Peel, D. A., Ziogas, A., et al. (1999) · PubMed · Cited by 324
BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas.
Chan, T. L., Zhao, W., Leung, S. Y., & Yuen, S. T. (2003) · PubMed · Cited by 319
Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis
Arber, N., Hibshoosh, H., Moss, S., Sutter, T., Zhang, Y., Begg, M., Wang, S., Weinstein, I., & Holt, P. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8608874 · Cited by 313 · cited 1×
“Arber and colleagues evaluated the presence of CCND1 in normal colonic mucosa, adenoma and adenocarcinoma and confirm its increased expression only in mucosa from individuals affected by CRC [27].”
BackgroundParsons, M. T., Buchanan, D. D., Thompson, B., Young, J. P., & Spurdle, A. B. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2011-100714 · Cited by 311 · cited 1×
“Importantly, sporadic MSI-high CRC cases harbor the V600E mutation of the BRAF oncogene, a member of the RAF family involved in the mediation of cellular response to the growth signal through the RAS-RAF-MAP kinase [75].”
BackgroundSinicrope, F. A., & Sargent, D. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1469 · Cited by 309
Leary, R. J., Lin, J. C., Cummins, J., Boca, S., Wood, L. D., Parsons, D. W., Jones, S., Sjöblom, T., Park, B.-H., Parsons, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808041105 · Cited by 306 · cited 1×
“instability (CIN) pathway, characterized by widespread loss of heterozygosis (LOH) and gross chromosomal abnormalities [8,9].”
BackgroundHypermethylation can selectively silence individual p16ink4A alleles in neoplasia.
Myöhänen, S., Baylin, S. B., & Herman, J. G. (1998) · PubMed · Cited by 302
Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome
Burn, J., Bishop, D. T., Mecklin, J.-P., Macrae, F., Möslein, G., Olschwang, S., Bisgaard, M.-L., Ramesar, R., Eccles, D., Maher, E. R., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801297 · Cited by 300
Kaidi, A., Qualtrough, D., Williams, A. C., & Paraskeva, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0425 · Cited by 300 · cited 4×
“Interestingly, COX-2-positive tumors were found to be associated with an increased cancer-specific mortality regardless of p53 status, indicating that COX-2 could be an independent prognostic factor of colorectal cancers [42].”
BackgroundInfluentialOverexpression and mistargeting of centromere protein-A in human primary colorectal cancer.
Tomonaga, T., Matsushita, K., Yamaguchi, S., 大橋, 建., Shimada, H., Ochiai, T., Yoda, K., & Nomura, F. (2003) · PubMed · Cited by 298
Serum interleukin-6 levels in colorectal cancer patients—a summary of published results
Knüpfer, H., & Preiss, R. (2010) · International Journal of Colorectal Disease · doi:10.1007/s00384-009-0818-8 · Cited by 291 · cited 1×
“Moreover, Knupfer and colleagues found higher levels of IL-6 in neoplastic colorectal mucosa than in normal mucosa and strong associations between advanced CRC stage, tumor size and a worse prognosis [126].”
BackgroundFrequency of Smad gene mutations in human cancers.
Riggins, G. J., Kinzler, K. W., Vogelstein, B., & Thiagalingam, S. (1997) · PubMed · Cited by 285
HIF1A Overexpression Is Associated with Poor Prognosis in a Cohort of 731 Colorectal Cancers
Baba, Y., Nosho, K., Shima, K., Irahara, N., Chan, A. T., Meyerhardt, J. A., Chung, D. C., Giovannucci, E. L., Fuchs, C. S., & Ogino, S. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090972 · Cited by 285 · cited 6×
“Importantly HIF1α over-expression was significantly associated with shorter colorectal cancer-specific survival and overall survival [55].”
BackgroundInfluentialmRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer
Lanza, G., Ferracin, M., Gafà, R., Veronese, A., Spizzo, R., Pichiorri, F., Liu, C.-G., Calin, G. A., Croce, C. M., & Negrini, M. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-54 · Cited by 285 · cited 2×
“Interestingly, Lanza et al. found significant upregulations of miR-17-92, miR-17-5p, miR-20, miR25, miR-92-1, miR-92-2, miR-93-1 and miR-106a in the microsatellite stable (MSS) CRC and not in MSI CRC [116].”
Notch post-translationally regulates β-catenin protein in stem and progenitor cells
Kwon, C., Cheng, P., King, I. N., Andersen, P., Shenje, L., Nigam, V., & Srivastava, D. (2011) · Nature Cell Biology · doi:10.1038/ncb2313 · Cited by 284 · cited 2×
“This confirms the protective effects that have been extensively studied regarding the role of NSAIDs on colorectal cancer [21].”
BackgroundClinical and pathological associations with allelic loss in colorectal carcinoma [corrected]
Kern, S. E. (1989) · JAMA · doi:10.1001/jama.261.21.3099 · Cited by 271
Colorectal cancer: genetics of development and metastasis
Takayama, T., Miyanishi, K., Hayashi, T., Sato, Y., & Niitsu, Y. (2006) · Journal of Gastroenterology · doi:10.1007/s00535-006-1801-6 · Cited by 265 · cited 4×
“BAX gene mutations, like TGF-βRII mutations, can be present in neoplastic progressions despite early adenoma mutations [84].”
BackgroundInfluentialOgino, S., Kawasaki, T., Nosho, K., Ohnishi, M., Suemoto, Y., Kirkner, G. J., & Fuchs, C. S. (2008) · International Journal of Cancer · doi:10.1002/ijc.23470 · Cited by 261 · cited 2×
“Ogino revealed an inverse association between the MSI pathway and LINE-1 hypomethylation [50], and Baba and colleagues also confirmed a direct association between LINE-1 hypomethylation and chromosomal instability (CIN) [51].”
BackgroundFrameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype.
Yamamoto, H., Sawai, H., & Perucho, M. (1997) · PubMed · Cited by 253
Imamura, Y., Morikawa, T., Liao, X., Lochhead, P., Kuchiba, A., Yamauchi, M., Qian, Z. R., Nishihara, R., Meyerhardt, J. A., Haigis, K. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3210 · Cited by 249 · cited 2×
“Imamura and colleagues reinforced this hypothesis by confirming that the respective malignancy of the codon 12 and 13 mutations is independent of the BRAF mutations that are often associated with a poorer CRC prognosis: even after eliminating BRAF as a confounding factor, codon 12 mutations were implicated in signific…”
BackgroundGrady, W. M., Rajput, A., Myeroff, L. L., Liu, D. F., Kwon, K., Willis, J. E., & Markowitz, S. D. (1998) · PubMed · Cited by 244
Jass, J. R., Baker, K., Zlobec, I., Higuchi, T., Barker, M., Buchanan, D., & Young, J. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02466.x · Cited by 244 · cited 2×
“This is also frequently associated with mutations in the DNA repair gene Methylguanine Methyltransferase (MGMT) and with the loss of function of the PIK3CA [98,104,105].”
BackgroundGuerrero, S., Casanova, I., Farré, L., Mazo, A., Capellá, G., & Mangues, R. (2000) · PubMed · Cited by 243
Burn, J., Bishop, D. T., Chapman, P. D., Elliott, F., Bertario, L., Dunlop, M. G., Eccles, D., Ellis, A., Evans, D. G., Fodde, R., et al. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0106 · Cited by 241 · cited 1×
“However, results from the CAPP-1 [129]”
PIK3CA Mutation in Colorectal Cancer: Relationship with Genetic and Epigenetic Alterations
Nosho, K., Kawasaki, T., Longtine, J. A., Fuchs, C. S., Ohnishi, M., Suemoto, Y., Kirkner, G. J., Zepf, D., Yan, L., & Ogino, S. (2008) · Neoplasia · doi:10.1593/neo.08336 · Cited by 238 · cited 1×
“5%), Insulin Growth Factor Type 2 Receptor (IGFIIR) (22%), BLM gene (16%), PIK3CA (15%), G protein-coupled receptor of Prostaglandin-endoperoxide synthase 2 (PTGS2) (33%) and Cyclin D1 gene (28%) [86–90].”
BackgroundPhysical Activity and Colorectal Cancer
Slattery, M. L. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg134 · Cited by 234
Antimetastatic Role of Smad4 Signaling in Colorectal Cancer
Zhang, B., Halder, S. K., Kashikar, N. D., Cho, Y., Datta, A., Gorden, D. L., & Datta, P. K. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.004 · Cited by 221 · cited 1×
“Smad4 mutations facilitate the switch to the tumor-promoting role of TGF-β signaling [79].”
BackgroundCyclooxygenase-2 Expression Is an Independent Predictor of Poor Prognosis in Colon Cancer
Ogino, S., Kirkner, G. J., Nosho, K., Irahara, N., Kure, S., Shima, K., Hazra, A., Chan, A. T., Dehari, R., Giovannucci, E. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1841 · Cited by 209 · cited 2×
“p-AMPK Better survival among p-ERK positive [33] p53 expression Better survival among non obese [37] p21 loss Better survival for patients >60 yrs [38] COX-2-positive tumors Increased cancer specific mortality [42]”
BackgroundA Prospective Study of Serum C-Reactive Protein and Colorectal Cancer Risk in Men
Gunter, M. J., Stolzenberg-Solomon, R., Cross, A. J., Leitzmann, M. F., Weinstein, S., Wood, R. J., Virtamo, J., Taylor, P. R., Albanes, D., & Sinha, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3631 · Cited by 205 · cited 3×
“CRP is a biomarker of inflammation, both in the acute phase and in the chronic low phase of inflammation [122,123].”
BackgroundBelluco, C., Nitti, D., Frantz, M., Toppan, P., Basso, D., Plebani, M., Lise, M., & Jessup, J. M. (2000) · Annals of Surgical Oncology · doi:10.1007/s10434-000-0133-7 · Cited by 196 · cited 1×
“also found a significant association between elevated IL-6 serum levels and worse 5-years survival CRC [127].”
BackgroundBoland, C. R., Koi, M., Chang, D. K., & Carethers, J. M. (2008) · Familial Cancer · doi:10.1007/s10689-007-9145-9 · Cited by 193 · cited 1×
“The clinical manifestations can be diverse, depending upon which gene is involved and where the mutations occur [64].”
BackgroundPhysical Activity and Colorectal Cancer
Slattery, M. L. (2004) · Sports Medicine · doi:10.2165/00007256-200434040-00004 · Cited by 187
Mismatch repair, molecular switches, and signal transduction
Fishel, R. (1998) · Genes & Development · doi:10.1101/gad.12.14.2096 · Cited by 179 · cited 2×
“The MMR system acts only when an error eludes the intrinsic error checking system of DNA polymerase [59].”
BackgroundDual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability
Shin, H.-J., Baek, K.-H., Jeon, A.-H., Park, M.-T., Lee, S.-J., Kang, C.-M., Lee, H.-S., Yoo, S.-H., Chung, D.-H., Sung, Y.-C., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00302-7 · Cited by 172 · cited 1×
“pathogenic mechanism in the initiation of chromosomal instability in CRC sporadic forms [19].”
BackgroundPetko, Z., Ghiassi, M., Shuber, A., Gorham, J., Smalley, W., Washington, M. K., Schultenover, S., Gautam, S., Markowitz, S. D., & Grady, W. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1203.11.3 · Cited by 171
Baba, Y., Huttenhower, C., Nosho, K., Tanaka, N., Shima, K., Hazra, A., Schernhammer, E. S., Hunter, D. J., Giovannucci, E. L., Fuchs, C. S., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-125 · Cited by 160 · cited 15×
“A “key” initial mutation is the early mutation of the adenomatous polyposis coli (APC) tumor suppressor gene, involved in both sporadic CIN and, when germline mutated, in all Familial Adenomatous Polyposis (FAP) [12,13].”
BackgroundInfluentialChromosome 18q allelic loss and prognosis in stage II and III colon cancer
Lanza, G., Matteuzzi, M., Gafá, R., Orvieto, E., Maestri, I., Santini, A., & del Senno, L. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980821)79:4<390::aid-ijc14>3.0.co;2-9 · Cited by 141 · cited 3×
“4%) [43], where the genes Smad2, Smad4 and DCC genes are located.”
BackgroundDNMT3B Expression Might Contribute to CpG Island Methylator Phenotype in Colorectal Cancer
Nosho, K., Shima, K., Irahara, N., Kure, S., Baba, Y., Kirkner, G. J., Chen, L., Gokhale, S., Hazra, A., Spiegelman, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2383 · Cited by 140 · cited 1×
“DNA methyltransferase-3B (DMT3B) overexpression seems to play a role in establishing and maintaining the aformentioned methylation patterns [111].”
BackgroundLoss of activin receptor type 2 protein expression in microsatellite unstable colon cancers
Jung, B. H., Doctolero, R. T., Tajima, A., Nguyen, A. K., Keku, T. O., Sandler, R. S., & Carethers, J. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.008 · Cited by 139 · cited 1×
“mutations [81].”
Shima, K., Nosho, K., Baba, Y., Cantor, M., Meyerhardt, J. A., Giovannucci, E. L., Fuchs, C. S., & Ogino, S. (2011) · International Journal of Cancer · doi:10.1002/ijc.25432 · Cited by 137 · cited 1×
“function causes uncontrolled cell proliferation, leading to neoplastic transformation [95–98].”
BackgroundSieber, O. M., Lamlum, H., Crabtree, M. D., Rowan, A. J., Barclay, E., Lipton, L., Hodgson, S., Thomas, H. J. W., Neale, K., Phillips, R. K. S., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.042699199 · Cited by 136 · cited 6×
“adenomatous polyposis coli (APC) tumor suppressor gene, involved in both sporadic CIN and, when germline mutated, in all Familial Adenomatous Polyposis (FAP) [12,13].”
BackgroundInfluentialLanza, G., Gafà, R., Maestri, I., Santini, A., Matteuzzi, M., & Cavazzini, L. (2002) · Modern Pathology · doi:10.1097/01.mp.0000018979.68686.b2 · Cited by 132 · cited 3×
“and survival of patients affected by MSI-high CRC is better and longer than that of patients with CIN positive CRC [61].”
BackgroundChan, A. T., Ogino, S., Giovannucci, E. L., & Fuchs, C. S. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.041 · Cited by 132 · cited 2×
“03), but found no correlation with the other two markers [124].”
BackgroundHorst, D., Chen, J., Morikawa, T., Ogino, S., Kirchner, T., & Shivdasani, R. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3222 · Cited by 128 · cited 1×
“and colleagues demonstrated that high WNT activity was connected with increased MAPK signaling, in K-ras mutated CRC samples [32].”
BackgroundTomonaga, T., Matsushita, K., Ishibashi, M., Nezu, M., Shimada, H., Ochiai, T., Yoda, K., & Nomura, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3613 · Cited by 127 · cited 2×
“prominent induction of aneuploidy by CENP-H overexpression than CENP-A, and a characteristic CENP-H overexpression in CIN colorectal cell lines compared with MSI-H colorectal cell lines [53].”
BackgroundThe Prognostic Value of MicroRNAs Varies with Patient Race/Ethnicity and Stage of Colorectal Cancer
Bovell, L. C., Shanmugam, C., Putcha, B.-D. K., Katkoori, V. R., Zhang, B., Bae, S., Singh, K. P., Grizzle, W. E., & Manne, U. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3302 · Cited by 126 · cited 3×
“miR-21 Poor prognosis in patients with stage IV CRC [117]”
BackgroundInfluentialOgino, S., Nosho, K., Irahara, N., Shima, K., Baba, Y., Kirkner, G. J., Meyerhardt, J. A., & Fuchs, C. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8858 · Cited by 121 · cited 2×
“decreased survival in colorectal cancer patients [45].”
BackgroundProgressive methylation during the serrated neoplasia pathway of the colorectum
Dong, S. M., Lee, E. J., Jeon, E. S., Park, C. K., & Kim, K. (2004) · Modern Pathology · doi:10.1038/modpathol.3800261 · Cited by 121 · cited 1×
“function causes uncontrolled cell proliferation, leading to neoplastic transformation [95–98].”
BackgroundConstitutive activation of Stat3 signaling pathway in human colorectal carcinoma
Ma, X.-T. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i11.1569 · Cited by 120 · cited 5×
“P53 also interacts with Cyclooxygenase-2 (COX-2), which plays a role in promoting inflammation and cell proliferation in CRC [41].”
BackgroundInfluentialOtani, T., Iwasaki, M., Sasazuki, S., Inoue, M., & Tsugane, S. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0708 · Cited by 119
Karyotypic characterization of colorectal adenocarcinomas
Bardi, G., Sukhikh, T., Pandis, N., Fenger, C., Kronborg, O., & Heim, S. (1995) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870120204 · Cited by 118 · cited 1×
“The tumorigenic process involves different mitotic spindle checkpoint regulators and proteins that mutually influence mitotic chromosome stability [10,11].”
BackgroundItalian mediterranean index and risk of colorectal cancer in the Italian section of the EPIC cohort
Agnoli, C., Grioni, S., Sieri, S., Palli, D., Masala, G., Sacerdote, C., Vineis, P., Tumino, R., Giurdanella, M. C., Pala, V., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.27740 · Cited by 109 · cited 1×
“Physical activity [4], long-term therapy with low-dose aspirin [5], and the Mediterranean diet [6] have proved to have possible preventive effects.”
BackgroundFirestein, R., Shima, K., Nosho, K., Irahara, N., Baba, Y., Bojarski, E., Giovannucci, E. L., Hahn, W. C., Fuchs, C. S., & Ogino, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.24908 · Cited by 109 · cited 2×
“CDK8 overexpression Poor prognosis [24]”
BackgroundOgino, S., Kawasaki, T., Kirkner, G. J., Suemoto, Y., Meyerhardt, J. A., & Fuchs, C. S. (2007) · Gut · doi:10.1136/gut.2007.119750 · Cited by 108 · cited 4×
“This is also frequently associated with mutations in the DNA repair gene Methylguanine Methyltransferase (MGMT) and with the loss of function of the PIK3CA [98,104,105].”
BackgroundInfluentialSuzuki, H., Igarashi, S., Nojima, M., Maruyama, R., Yamamoto, E., Kai, M., Akashi, H., Watanabe, Y., Yamamoto, H., Sasaki, Y., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp179 · Cited by 104
Calin, G. A., Gafà, R., Tibiletti, M. G., Herlea, V., Becheanu, G., Cavazzini, L., Barbanti‐Brodano, G., Nenci, I., Negrini, M., & Lanza, G. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000520)89:3<230::aid-ijc4>3.0.co;2-j · Cited by 103
Ogino, S., Odze, R. D., Kawasaki, T., Brahmandam, M., Kirkner, G. J., Laird, P. W., Loda, M., & Fuchs, C. S. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213266.84725.d0 · Cited by 102 · cited 1×
“CIMP is found in approximately 20%–30% of CRC and it was reported that clinical features of CIMP CRCs are similar to those associated with MSI [94].”
ResultYagi, O. K., Akiyama, Y., Nomizu, T., Iwama∥, T., Endo, M., & Yuasa, Y. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70477-9 · Cited by 94 · cited 1×
“present in neoplastic progressions despite early adenoma mutations [84].”
BackgroundMarchand, L. L., Wilkens, L. R., Hankin, J. H., Kolonel, L. N., & Lyu, L.-C. (1997) · Cancer Causes & Control · doi:10.1023/a:1018406716115 · Cited by 92 · cited 1×
“Several epidemiological studies have confirmed the involvement of numerous environmental and dietary factors, such as cigarette smoking, alcohol abuse, a diet high in fat and low in fiber, a sedentary lifestyle and obesity [3].”
BackgroundA Cohort Study of Cyclin D1 Expression and Prognosis in 602 Colon Cancer Cases
Ogino, S., Nosho, K., Irahara, N., Kure, S., Shima, K., Baba, Y., Toyoda, S., Chen, L., Giovannucci, E. L., Meyerhardt, J. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3330 · Cited by 89
Swamy, M. V., Herzog, C. R., & Rao, C. V. (2003) · PubMed · Cited by 89
Baba, Y., Nosho, K., Shima, K., Meyerhardt, J. A., Chan, A. T., Engelman, J. A., Cantley, L. C., Loda, M. F., Giovannucci, E. L., Fuchs, C. S., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605846 · Cited by 86 · cited 2×
“p-AMPK Better survival among p-ERK positive [33] p53 expression Better survival among non obese [37] p21 loss Better survival for patients >60 yrs [38] COX-2-positive tumors Increased cancer specific mortality [42]”
BackgroundPIK3CA and APC mutations are synergistic in the development of intestinal cancers
Deming, D. A., Leystra, A. A., Nettekoven, L., Sievers, C., Miller, D., Middlebrooks, M., Clipson, L., Albrecht, D., Bacher, J., Washington, M. K., et al. (2014) · Oncogene · doi:10.1038/onc.2013.167 · Cited by 78 · cited 2×
“An alteration that often occurs simultaneously with APC gene mutations is found in the phosphoinositide-3 kinase (PI3KCA) signaling pathway [46], which triggers the activation of different nuclear transcriptional factors through a kinase cascade.”
BackgroundBardi, G., Johansson, B., Pandis, N., Mandahl, N., Mitelman, F., Heim, S., Bak-Jensen, E., Lindström, C., Törnqvist, A., Frederiksen, H. J., et al. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550317 · Cited by 77 · cited 1×
“The tumorigenic process involves different mitotic spindle checkpoint regulators and proteins that mutually influence mitotic chromosome stability [10,11].”
BackgroundMGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers
Shima, K., Morikawa, T., Baba, Y., Nosho, K., Suzuki, M., Yamauchi, M., Hayashi, M., Giovannucci, E. L., Fuchs, C. S., & Ogino, S. (2010) · Cancer Causes & Control · doi:10.1007/s10552-010-9698-z · Cited by 75 · cited 4×
“This is also frequently associated with mutations in the DNA repair gene Methylguanine Methyltransferase (MGMT) and with the loss of function of the PIK3CA [98,104,105].”
BackgroundInfluentialMorikawa, T., Kuchiba, A., Lochhead, P., Nishihara, R., Yamauchi, M., Imamura, Y., Liao, X., Qian, Z. R., Ng, K., Chan, A. T., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2276 · Cited by 70
Kawasaki, T., Ohnishi, M., Nosho, K., Suemoto, Y., Kirkner, G. J., Meyerhardt, J. A., Fuchs, C. S., & Ogino, S. (2008) · Modern Pathology · doi:10.1038/modpathol.3800982 · Cited by 70 · cited 1×
“CIMP-low, in contrast with CIMP-high, appears to have different phenotype, with a low-level of DNA methylation [106].”
Backgroundp21 Expression in Colon Cancer and Modifying Effects of Patient Age and Body Mass Index on Prognosis
Ogino, S., Nosho, K., Shima, K., Baba, Y., Irahara, N., Kirkner, G. J., Hazra, A., De Vivo, I., Giovannucci, E. L., Meyerhardt, J. A., et al. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0451 · Cited by 69
Transcriptional Control of BubR1 by p53 and Suppression of Centrosome Amplification by BubR1
Oikawa, T., Okuda, M., Ma, Z., Goorha, R., Tsujimoto, H., Inokuma, H., & Fukasawa, K. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.10.4046-4061.2005 · Cited by 68 · cited 1×
“Oikawa demonstrated that p53 largely controlled BubR1 transcription and expression and, in patients with 17p Loss of Heterozygosity (LOH), BubR1 activity was significantly downregulated [35].”
BackgroundChan, A. T., Baba, Y., Shima, K., Nosho, K., Chung, D. C., Hung, K. E., Mahmood, U., Madden, K., Poss, K., Ranieri, A., et al. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0529 · Cited by 68 · cited 2×
“PI3KCA mutations Increased survival among chronic aspirin users [48] Line-1 Hypomethylation Young age of onset and increased cancer and overall mortality [50,51] HIF1 High colorectal cancer-specific mortality [55] Cathepsin B expression High colorectal cancer and overall mortality [57] MSI Better prognosis and surviva…”
BackgroundOgino, S., Kawasaki, T., Ogawa, A., Kirkner, G. J., Loda, M. F., & Fuchs, C. S. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.11.018 · Cited by 67
Ogino, S., Kawasaki, T., Kirkner, G. J., Yamaji, T., Loda, M. F., & Fuchs, C. S. (2006) · Modern Pathology · doi:10.1038/modpathol.3800709 · Cited by 65 · cited 1×
“and colleagues also found that the silencing, and subsequently the downregulation, of cyclin-dependent kinase inhibitor-1B (CDKM1B or p27) was associated with CIMP-high CRC and, like IGFBP7, was associated with dysfunctions in p53 [110].”
BackgroundColorectal Cancer and Serum C-reactive Protein Levels: a Case-control Study Nested in the JACC Study
Ito, Y., Suzuki, K. A. O., Tamakoshi, K., Wakai, K., Kojima, M., Ozasa, K., Watanabe, Y., Kawado, M., Hashimoto, S., Suzuki, S., et al. (2005) · Journal of Epidemiology · doi:10.2188/jea.15.s185 · Cited by 63 · cited 1×
“patients affected by CRC, no association between CRP levels and the risk of CRC was found [128].”
BackgroundA prospective study of plasma inflammatory markers and risk of colorectal cancer in men
Song, M., Wu, K., Ogino, S., Fuchs, C. S., Giovannucci, E. L., & Chan, A. T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.172 · Cited by 62
Prospective Study of Family History and Colorectal Cancer Risk by Tumor LINE-1 Methylation Level
Ogino, S., Nishihara, R., Lochhead, P., Imamura, Y., Kuchiba, A., Morikawa, T., Yamauchi, M., Liao, X., Qian, Z. R., Sun, R., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs482 · Cited by 61 · cited 1×
“Researchers have also found that this pathway presents specific clinical features, characterized by a young age of onset of CRC (<60 years old) and a more aggressive behavior [51,52].”
BackgroundRicciardiello, L., Ceccarelli, C., Angiolini, G., Pariali, M., Chieco, P., Paterini, P., Biasco, G., Martinelli, G. N., Roda, E., & Bazzoli, F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0141 · Cited by 61 · cited 1×
“promoter [71–74].”
Self-citationTumor TP53 expression status, body mass index and prognosis in colorectal cancer
Morikawa, T., Kuchiba, A., Liao, X., Imamura, Y., Yamauchi, M., Qian, Z. R., Nishihara, R., Sato, K., Meyerhardt, J. A., Fuchs, C. S., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.26495 · Cited by 57 · cited 2×
“p-AMPK Better survival among p-ERK positive [33] p53 expression Better survival among non obese [37] p21 loss Better survival for patients >60 yrs [38] COX-2-positive tumors Increased cancer specific mortality [42]”
BackgroundShima, K., Morikawa, T., Yamauchi, M., Kuchiba, A., Imamura, Y., Liao, X., Meyerhardt, J. A., Fuchs, C. S., & Ogino, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025062 · Cited by 57
Loss of Heterozygosity and DNA Aneuploidy in Colorectal Adenocarcinoma
Lin, J.-K., Chang, S., Yang, Y., & Li, A. F. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.12.014 · Cited by 54 · cited 1×
“instability (CIN) pathway, characterized by widespread loss of heterozygosis (LOH) and gross chromosomal abnormalities [8,9].”
BackgroundKastrinos, F., Steyerberg, E. W., Balmañà, J., Mercado, R. C., Gallinger, S., Haile, R. W., Casey, G., Hopper, J. L., Marchand, L. L., Lindor, N. M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301265 · Cited by 53 · cited 1×
“high suspected HNPCC, clinical parameters can help direct new suspected cases toward targeted genetic testing [70].”
BackgroundNosho, K., Kawasaki, T., Chan, A. T., Ohnishi, M., Suemoto, Y., Kirkner, G. J., Fuchs, C. S., & Ogino, S. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03161.x · Cited by 51 · cited 1×
“5%), Insulin Growth Factor Type 2 Receptor (IGFIIR) (22%), BLM gene (16%), PIK3CA (15%), G protein-coupled receptor of Prostaglandin-endoperoxide synthase 2 (PTGS2) (33%) and Cyclin D1 gene (28%) [86–90].”
BackgroundMicrosatellite instability and mismatch repair defects in cancer cells
Thomas, D. C., Umar, A., & Kunkel, T. A. (1996) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(95)00112-3 · Cited by 44 · cited 1×
“Disabled DNA MMR causes a 100-fold increase in the mutation rate in colorectal mucosa cells [58].”
BackgroundBaba, Y., Nosho, K., Shima, K., Goessling, W., Chan, A. T., Ng, K., Chan, J. A.-W., Giovannucci, E. L., Fuchs, C. S., & Ogino, S. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-1154 · Cited by 42 · cited 1×
“Recently, Baba and colleagues found that G protein-coupled receptor PTGER2 overexpression, the downstream target of PGE2, which is involved in inflammation and cancer, is strongly associated with MSI [88].”
BackgroundPérez‐Cabornero, L., Infante, M., Velasco, E. A., Aras, E. L., Acedo, A., Pino, C. M., & Domínguez, M. D. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0080 · Cited by 39 · cited 1×
“Recently, a subclass of the MMR deficient HNPCC families have been found to carry germline deletions of the Epithelial Cell Adhesion Molecule (EpCAM) resulting in hMSH2 gene silencing [69].”
BackgroundOgino, S., Kawasaki, T., Ogawa, A., Kirkner, G. J., Loda, M. F., & Fuchs, C. S. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.09.014 · Cited by 25 · cited 2×
“Another CDK associated with p53 mutations is with CDK inhibitor 1B (CDKN1B or p27) [39].”
Background
Cited by
Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors
Rawla, P., Sunkara, T., & Barsouk, A. (2019) · Gastroenterology Review · doi:10.5114/pg.2018.81072 · Cited by 2,323
“In such patients, the efficacy of neoadjuvant, cytotoxic therapies has been stifled by the rapid evolution of drug resistance and cancer recurrence [8].”
BackgroundKuipers, E. J., Grady, W. M., Lieberman, D., Seufferlein, T., Sung, J. J., Boelens, P. G., van de Velde, C. J. H., & Watanabe, T. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.65 · Cited by 1,563
Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis
Mima, K., Nishihara, R., Qian, Z. R., Cao, Y., Sukawa, Y., Nowak, J. A., Yang, J., Dou, R., Masugi, Y., Song, M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310101 · Cited by 1,080
Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers
Okugawa, Y., Grady, W. M., & Goel, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.011 · Cited by 782
Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements
Malki, A., ElRuz, R. A., Gupta, I., Allouch, A., Vranic, S., & Al Moustafa, A.-E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010130 · Cited by 398
“Additionally, a wild type of p53 is identified as a direct activator for WAD-1, a gene highly induced to suppress tumor cell growth in the p53 pathway [81].”
Background
Metadata
- Authors
- Colussi, D., Brandi, G., Bazzoli, F., & Ricciardiello, L.
- Affiliations
- University of Bologna (IT)
- Corresponding author
- Ricciardiello, Luigi
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2013-08-07
- Volume
- 14
- Issue
- 8
- Pages
- 16365-16385
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC3759916
- OpenAlex
- W2011995257
- Cited by
- 429
- References
- 140
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 18 · 2023: 24 · 2022: 38 · 2021: 30 · 2020: 34 · 2019: 41 · 2018: 42 · 2017: 54 · 2016: 41 · 2015: 46 · 2014: 35 · 2013: 1
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- colorectal cancer, colorectal carcinogenesis, chromosomal instability, microsatellite instability, CpG island methylator phenotype, inflammation, microRNA, epigenetic modifications, genetic alterations, prognosis, survival, aspirin, chemoprevention, molecular markers, drug response
- MeSH terms
- Adenocarcinoma, Animals, Antineoplastic Agents, Aspirin, Humans, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Anticarcinogenic Agents, Inflammation Mediators, Microsatellite Repeats, DNA Methylation, Chromosomal Instability, Wnt Signaling Pathway
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.